Speaking to CNBC on January 13, Ari Wald, Head of Technical Analysis at Oppenheimer, said U.S. equity markets still appear to be in a healthy bull cycle, based on technical signals rather than fundamentals. Wald said that Oppenheimer’s 2026 target for the S&P 500 is 7,700, reflecting expectations for further upside. He acknowledged that the market is now in a later stage of the cycle, which typically raises concerns about a peak. However, he emphasized that the typical warning signs of a market top are not yet visible.
Interestingly, Wald believes market breadth is improving, which is a positive sign. He argued that smaller stocks, particularly the Russell 2000, are breaking above long-standing resistance levels, suggesting that gains are spreading beyond just large-cap stocks. Wald thinks that the market’s gains are not limited to just a few large technology stocks. While he still views technology as the long-term leader, he said the current phase is characterized by broader participation across sectors and regions.
As equity markets are expected to inch higher, Morgan Stanley Research also recently shared similar views and recommended an overweight position in stocks, particularly in US assets.
According to a Morgan Stanley note from November, U.S. equities should outperform global peers in 2026, with the S&P 500 increasing 14% to 7,800 in the next 12 months, compared with expected gains of 7% for Japan’s TOPIX and 4% for the MSCI Europe. U.S. earnings and revenue growth are positioned to benefit from several factors, including a market-friendly policy mix, interest-rate cuts by the Federal Reserve, and a $129 billion cut in corporate tax bills through 2026 and 2027 under the One Big Beautiful Act.
“There will be some bumps along the way, but we believe that the bull market is intact,” Serena Tang, Morgan Stanley’s Chief Global Cross-Asset Strategist, said.
In such a supportive environment, one strategy is to consider U.S. stocks with high revenue growth by targeting companies with rapidly expanding top-line sales, often in tech, biotech, or other emerging sectors. Investors prioritize future potential over current profits, betting on compounding returns as these firms scale.
With this in mind, let’s take a look at the 13 Best Revenue Growth Stocks to Buy Right Now.
Our Methodology
To curate the list of 13 best revenue growth stocks to buy right now, we used the Stock Analysis Screener and Insider Monkey’s Q3 2025 database. Using the screener, we compiled a list of US stocks with a market cap over $2 billion, a 3-year revenue growth rate of at least 20%, and analyst coverage from at least three analysts. Next, we ranked the stocks in ascending order of upside percentage. We have also included the number of hedge funds holding the stock, based on Insider Monkey’s hedge fund database, which tracks 978 stocks as of Q3 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
13. TG Therapeutics Inc (NASDAQ:TGTX)
Price Target Upside: 75.33%
Number of Hedge Fund Holders: 37
TG Therapeutics Inc. (NASDAQ:TGTX) is one of the best revenue growth stocks to buy right now.
On February 2, JPMorgan analyst Brian Cheng reduced the price target on TG Therapeutics to $46 from $49 while maintaining the Overweight rating on the shares. The investment bank had recently updated the model on the company.
TG Therapeutics is set to present its trial results on February 6 at a medical forum in San Diego, California. The presentation will focus on the results of its Briumvi treatment for relapsing multiple sclerosis in adults.
Earlier, in mid-January, H.C. Wainwright analyst Emily Bodnar gave a Buy rating on the stock, citing the company’s strong commercial momentum and anticipated clinical catalysts in 2026. These include results for consolidated IV dosing and self-administered subcutaneous formulation for Briumvi, which could boost its market share against competing therapies.
On January 29, TD Cowen analyst Tara Bancroft reiterated a Buy rating on TG Therapeutics and set a $50 price target.
TG Therapeutics Inc. (NASDAQ:TGTX) is a biopharmaceutical company engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
12. Intapp Inc (NASDAQ:INTA)
Price Target Upside: 76.73%
Number of Hedge Fund Holders: 28
Intapp Inc (NASDAQ:INTA) is one of the Best Revenue Growth Stocks to Buy Right Now.
On February 4, Intapp saw its stock price target reduced by a number of firms. Truist lowered the price target on the stock to $35 from $68, BofA to $50 from $76, UBS to $54 from $62, Stifel to $40 from $50, and JPMorgan to $58 from $70.
Intapp had reported its Q2 results a day earlier on February 2. The company’s Q2 EPS was $0.33, exceeding the consensus of $0.26, while revenue was $140.2 million, beating the consensus of $138.2 million. The quarter’s results were supported by the addition of new clients and the expansion of existing client accounts, according to Intapp CEO John Hall. “Our results reflect our proficiency in serving enterprise clients, our growing partner ecosystem, and demand for our new AI-driven solutions in the highly-regulated industries we serve,” he said.
Intapp’s board said it authorized a common stock repurchase program of up to $200 million. The share repurchase program follows the $150.0 million share repurchase program previously authorized in August 2025, which has been completed.
Intapp, Inc. is a software company that provides IT services and industry-specific, cloud-based solutions for the global professional and financial services industry.
11. Remitly Global, Inc. (NASDAQ:RELY)
Price Target Upside: 88.35%
Number of Hedge Fund Holders: 38
Remitly Global, Inc. (NASDAQ:RELY) is one of the Best Revenue Growth Stocks to Buy Right Now.
On January 26, Cantor Fitzgerald initiated coverage of Remitly Global with an Overweight rating and $17 price target.
According to a research note from the investment bank, the company is poised to gain further market share in a highly fragmented, competitive landscape. The anticipated growth is also set against a backdrop of rising digital remittances, the note said. While recent stock performance reflects sentiment headwinds, Remitly’s fundamentals remain “quite strong,” with operating leverage expected to drive significant margin expansion, earnings growth, and free cash flow, according to the note.
Earlier this month, Wolfe Research analyst Darrin Peller maintained a Buy rating on Remitly Global and set a $16 price target.
As of February 2, Remitly Global, Inc. (NASDAQ:RELY) is a consensus Buy with all 9 analysts covering it assigning a Buy rating. The company also appears to benefit from a strong outlook, as even the lowest analyst price target implies a 25% upside. Overall, the consensus 1-year median price target of $19.50 implies an over 88% upside.
Remitly Global, Inc. is a digital remittances financial technology company enabling fast, low-cost cross-border money transfers.
10. Duolingo Inc (NASDAQ:DUOL)
Price Target Upside: 102.89%
Number of Hedge Fund Holders: 50
Duolingo Inc (NASDAQ:DUOL) is one of the Best Revenue Growth Stocks to Buy Right Now.
On January 27, DA Davidson cut the price target on Duolingo (DUOL) to $170 from $205 and maintained a Neutral rating on the shares.
According to a research note from the firm, Duolingo saw its highest month-over-month increase in users in January, since the language-learning company started tracking the figures in July 2025. However, data extrapolation showed that Daily Active Users (DAU) came in about 4% below current consensus estimates, implying a year-over-year growth rate of 19%-20%, compared with a consensus of 25%, according to the note. The platform currently has more than 170,000 existing users.
DA Davidson noted that the company still commanded a gross profit margin of around 72% and close to 40% revenue growth over the last twelve months.
In the past month, research firms mostly maintained their ratings on the stock, with J.P. Morgan, Citi, Evercore ISI, and Truist Securities all maintaining Buy ratings. On January 13, Morgan Stanley lowered Duolingo’s price target to $275 from $300 while maintaining an Overweight rating.
Duolingo, Inc. is an educational technology company that operates a language-learning website and mobile application. It has expanded to offer courses in math, music, chess, and literacy, reaching over 135 million monthly active users.
9. Roblox Corp (NYSE:RBLX)
Price Target Upside: 105.51%
Number of Hedge Fund Holders: 90
Roblox Corp (NYSE:RBLX) is one of the Best Revenue Growth Stocks to Buy Right Now.
On February 5, the company reported strong Q4 2025 results that, along with Q1 2026 guidance, exceeded Street expectations (as per CNBC report). While fourth-quarter bookings grew 63% to $2.22 billion, ahead of consensus at $2.05 billion, average daily active users rose 69% to 144 million, above the 138 million estimate. In addition, Q1 2026 bookings are expected to be between $1.69 and $1.74 billion, ahead of the Street’s $1.68 billion expectation.
Before the results, on February 2, Jefferies analyst Brent Thill had argued that the rollout of Google’s (GOOGL) Project Genie pressured game stocks, including Roblox (RBLX). The project is an experimental prototype that allows users to create and explore interactive 3D worlds, raising concerns about potential disruption to game engine developers, including Roblox. However, Roblox is more likely to establish a partnership and add more world models to its game engine, the analyst said. Jefferies has a Hold rating on the gaming company.
On the same day, Deutsche Bank analysts said the risk-reward profile for the company has “meaningfully improved” after the stock selloff triggered by Google’s announcement. The analysts said it’s “far too early” to measure the disruption caused by the development, and argued that there are scenarios where “Genie could be a tailwind” for the impacted companies. Genie “will not replace game development, nor will it disrupt the current mobile game discovery ecosystem,” the analysts said.
For Piper Sandler, the stock selloff in game stocks, including Roblox, is “indiscriminate and overdone,” according to a February 1 note.
Roblox Corp. is a video game developer and operates platforms that provide online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud.
8. Atlassian Corp (NASDAQ:TEAM)
Price Target Upside: 106.96%
Number of Hedge Fund Holders: 60
Atlassian Corp (NASDAQ:TEAM) is one of the Best Revenue Growth Stocks to Buy Right Now.
On February 2, Canaccord Genuity analyst David Hynes maintained a Buy rating on Atlassian with a price target of $230.
Zeroing in on a disconnect between Atlassian’s current valuation and its fundamentals, the analyst said the company’s stock price is down due to sector-wide multiple compression and AI-related concerns, despite its business performance, resilient growth, and improving margins. Hynes further argued that the company’s moves in pricing, product upgrades, cross-selling, and emerging consumption models can significantly improve the revenue run rate over time.
Hynes said he expects fiscal Q2 revenue growth to surpass guidance, potentially enabling the company to boost full-year cloud targets.
In the past month, research firms mostly lowered their price targets on the stock, with UBS cutting the price target to $145 from $185, BofA to $170 from $200, Baird to $170 from $230, Mizuho to $225 from $245, and TD Cowen to $175 from $205.
Atlassian Corp. is an enterprise software company that delivers team collaboration and productivity tools. Its products include Jira Software, Confluence, Jira Service Management, and Loom.
7. Braze Inc (NASDAQ:BRZE)
Price Target Upside: 114.84%
Number of Hedge Fund Holders: 34
Braze Inc (NASDAQ:BRZE) is one of the Best Revenue Growth Stocks to Buy Right Now.
On February 2, Piper Sandler cut the price target on Braze (BRZE) to $30 from $50 and maintained an Overweight rating on the company’s shares.
In a broad sweep, Piper downgraded three names and cut price targets across the platforms and apps group, because “seat-compression and vibe coding narratives could set a ceiling on multiples,” according to a research note. Software will continue to experience “pessimism,” while the hyperscaler, consumption, and vertical sub-sectors should fare better, according to the note.
On January 28, Goldman Sachs also lowered the price target on Braze to $45 from $55, as well as kept its Buy rating on the stock.
Earlier in the month, Needham analyst Scott Berg maintained a Buy rating on the stock with a price target of $50, citing operational improvements, product innovations, and positive demand signs. The analyst commended the company’s strategic execution, with its data-first customer engagement platform as a good fit, as more and more firms focus on automation and agentic commerce.
Braze, Inc. operates a customer relationship management platform for mobile applications. Its application combines messaging, audience segmentation, analytics, and user support in a single integrated solution.
6. HubSpot Inc (NYSE:HUBS)
Price Target Upside: 116.45%
Number of Hedge Fund Holders: 63
HubSpot Inc (NYSE: HUBS) is one of the Best Revenue Growth Stocks to Buy Right Now.
HubSpot Inc. (NYSE: HUBS) was also affected by the broad sweep across the sub-sector in a February 2 note by Piper Sandler, which lowered its target price on the company to $400 from $590 and maintained an Overweight rating on the shares.
Piper downgraded three names and cut price targets across the platforms and apps group, because “seat-compression and vibe coding narratives could set a ceiling on multiples,” according to a research note. Software will continue to experience “pessimism,” while the hyperscaler, consumption, and vertical sub-sectors should fare better, according to the note.
In the past month, several research firms cut their price targets on HubSpot: BMO Capital lowered its target to $385 from $465, UBS to $450 from $600, Goldman Sachs to $517 from $612, and Morgan Stanley to $577 from $640.
HubSpot, Inc. is a customer platform company focused on cloud-based customer relationship management. Its platform includes marketing, sales, service, operations, and a content management system, as well as other tools, integrations, and native payment solutions.
5. Monday.Com Ltd (NASDAQ:MNDY)
Price Target Upside: 122.73%
Number of Hedge Fund Holders: 55
Monday.Com Ltd (NASDAQ:MNDY) is one of the Best Revenue Growth Stocks to Buy Right Now.
On February 2, UBS and Piper Sandler reduced their price targets on Monday.Com stock to $140 from $200, and to $170 from $250, respectively.
A day earlier, Citi analyst Steve Enders kept a Buy rating on Monday.Com and lowered the price target to $230 from $293 due to the company’s current valuation being overly depressed relative to its fundamentals and market peers.
Although there is a risk to the company’s 2026 estimates and there will likely be a reduction in guidance, the analyst said these have been reflected in its share price, which has dipped sharply in the past months. Enders said the stock is trading at a significant discount to its peers, which could mean an upside if the market resets expectations.
Despite near-term uncertainty around the company, the analyst maintains a constructive long-term view, with Monday.Com potentially benefiting from AI capabilities. An analysis of web traffic trends also shows strong growth in overall site visits, paid search, and reallocated digital marketing spend, which point to a healthy demand environment, he said.
Monday.Com Ltd. provides a cloud-based Work OS platform that enables teams to build custom apps, workflows, and project management tools using no-code visual boards.
4. Wave Life Sciences Ltd (NASDAQ:WVE)
Price Target Upside: 131.38%
Number of Hedge Fund Holders: 38
Wave Life Sciences Ltd (NASDAQ:WVE) is one of the Best Revenue Growth Stocks to Buy Right Now.
On February 2, Wave Life Sciences Ltd. (WVE) said it regained full rights to WVE-006, a potential treatment for alpha-1 antitrypsin deficiency, a rare genetic disorder, from GSK. There are currently no approved therapies to address the lung and liver manifestations of the disease. It is one of the largest rare-disease indications, affecting 200,000 individuals in the U.S. and Europe.
Wave Life said it is accelerating its strategy for the drug and plans to meet with the U.S. Food and Drug Administration on a potential accelerated approval pathway, with regulatory feedback expected mid-2026.
The collaboration between Wave Life and GSK continues, under which Wave Life is eligible for up to $2.8 billion in initiation, development, launch, and commercialization milestones, as well as tiered royalties. Its cash runway is sufficient to fund operations into the third quarter of 2028.
On the same day, Wedbush analyst Yun Zhong maintained a Buy rating on the company’s stock with a price target of $33.
Wave Life Sciences Ltd. is a clinical-stage biotechnology company, pioneering RNA-based genetic medicines using its proprietary PRISM platform for stereopure oligonucleotides.
3. Trade Desk Inc (NASDAQ:TTD)
Price Target Upside: 136.60%
Number of Hedge Fund Holders: 42
Trade Desk Inc (NASDAQ:TTD) is one of the Best Revenue Growth Stocks to Buy Right Now.
On February 2, Cathie Wood’s ARK ETF divested a significant portion of its holdings in Trade Desk Inc (TTD), offloading 1,931,578 shares for nearly $58.6 million.
Earlier in the month, Wells Fargo maintained an Equal Weight rating on the stock with a price target of $42. In a research note, Wells Fargo said the sudden resignation of the company’s chief financial officer is a sign of “continued fundamental and narrative volatility.”
Management turnover is likely a factor that makes it harder for Trade Desk to compete with Amazon’s (AMZN) demand-side platform, according to the note. Wells Fargo recommends that the company seek a candidate with public-company CFO experience, which neither of its former CFOs had.
In the past month, a number of research firms cut their price targets on Trade Desk: Rosenblatt lowered the price target to $53 from $64, Truist to $60 from $65, Citi to $38 from $50, Stifel to $75 from $90, and BofA to $40 from $49.
Trade Desk is an independent demand-side platform for programmatic digital advertising, empowering ad buyers to purchase and optimize display, video, audio, and connected TV inventory across the open internet in real time.
2. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)
Price Target Upside: 203.74%
Number of Hedge Fund Holders: 55
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) is one of the Best Revenue Growth Stocks to Buy Right Now.
On January 30, Ultragenyx Pharmaceutical Inc. (RARE) resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration, seeking accelerated approval for UX111 AAV9 gene therapy as a treatment for patients with Sanfilippo syndrome type A (MPS IIIA).
The resubmitted BLA addresses the agency’s concerns regarding the drug. The company anticipates up to a six-month review period from the date of resubmission, which is expected in the third quarter. If approved, UX111 will be the first approved therapy for Sanfilippo syndrome type A.
On the same day, Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Ultragenyx Pharmaceutical with a price target of $50.
In the past month, Leerink Partners gave a Buy rating to Ultragenyx Pharmaceutical, while Wedbush reiterated its Hold rating on the stock.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing therapies for rare and ultra-rare genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza.
1. Legend Biotech Corp (NASDAQ:LEGN)
Price Target Upside: 267.03%
Number of Hedge Fund Holders: 28
Legend Biotech Corp (NASDAQ:LEGN) is one of the Best Revenue Growth Stocks to Buy Right Now.
In a board shakeup last month, Legend Biotech Corp (LEGN) appointed chairman and executive director of a major shareholder, GenScript, Robin Meng, as a Class III director to serve until the company’s 2026 annual general meeting, replacing outgoing director Li Zhu.
Directors Li Zhu and Yau Wai Man Philip resigned from the board, with Legend Biotech stating that the departures were not related to any dispute over operations or policies.
Earlier in the month, H. C. Wainwright lowered the price target on the stock to $50 from $60, while TD Cowen downgraded the stock to Hold from Buy, with a price target of $21.
On January 21, Legend Biotech reported preliminary net trade sales of approximately $555 million for its multiple myeloma cell therapy, CARVYKTI, for the quarter ended Dec. 31, 2025.
Legend Biotech Corp. is a clinical-stage biopharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications.
While we acknowledge the potential of LEGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LEGN and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 12 Best Software Infrastructure Stocks to Buy According to Hedge Funds and 11 Best Stocks You’ll Wish You Bought Sooner.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
